Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
ABSTRACT Nonalcoholic fatty liver disease (NAFLD), characterized by excessive fat deposition in the liver unrelated to alcohol consumption, is highly prevalent worldwide. However, effective therapeutic agents approved for NAFLD treatment are lacking. An ileal bile acid transporter inhibitor (IBATi),...
Enregistré dans:
Auteurs principaux: | Masahiro Matsui, Shinya Fukunishi, Takashi Nakano, Takaaki Ueno, Kazuhide Higuchi, Akira Asai |
---|---|
Format: | article |
Langue: | EN |
Publié: |
American Society for Microbiology
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9a0e2589159b4a369b5a6805e28b8614 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD
par: Norio Akuta, et autres
Publié: (2021) -
Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
par: Filip R, et autres
Publié: (2018) -
Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
par: Apollinariya V. Bogolyubova, et autres
Publié: (2017) -
White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in MiceSummary
par: Sadatsugu Sakane, et autres
Publié: (2021) -
A nomogram for predicting metabolic steatohepatitis: The combination of NAMPT, RALGDS, GADD45B, FOSL2, RTP3, and RASD1
par: Liao Shenling, et autres
Publié: (2021)